Huahui Ren
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Huahui Ren has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Fangming Yang
BGI Genomics, Shenzhen, China
2 shared publications- Huanzi Zhong
BGI Genomics, Shenzhen, China
2 shared publications Anders Isaksson
Science for Life Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
1 shared publication- Bengt Glimelius
Department of Immunology, Genetics and Pathology Uppsala University Uppsala Sweden
1 shared publication - Cong Lin
BGI-shenzhen, Shenzhen, China
1 shared publication Fengyi Yuan
Department of Endocrinology and Metabolism Shenzhen People's Hospital Shenzhen China
1 shared publication
Latest Publications
- Open Access
- 11 November 2026
- Published by Elsevier in Evolution and Human Behavior
- Vol. 48 (1)
Behavioral and physiological immunity under constraint: Pathogen disgust sensitivity relates to protein balance in chronic cardiovascular disease patients
- 11 November 2026
- Published by Elsevier in Evolution and Human Behavior
- Vol. 48 (1)
Open AccessBehavioral and physiological immunity under constraint: Pathogen disgust sensitivity relates to protein balance in chronic cardiovascular disease patients
- Open Access
- 7 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Tissue-resident microbiota impacts colorectal cancer progression and prognosis
To deepen the understanding of tissue-resident microbiota in colorectal cancer (CRC), we analyzed whole-genome and transcriptome data from 937 patients. We identified 249 genera and 361 species commonly present in both tumors and adjacent normal tissues (NATs). Distinct microbial signatures were associated with anatomical location, tumor stages, hypermutation status, mutations in CRC driver and DNA damage repair genes, as well as consensus molecular subtypes (CMSs). Notably, the presence of the pks island and elevated abundance of Enterobacteriaceae were linked to poor prognosis specifically in CMS2 tumors. Finally, microbial risk scores derived from taxa present in tumor or NATs predicted patient prognosis independently of established clinico-molecular factors. Prognostic taxa were strongly associated with tumor transcriptomic pathways related to hypoxia, immune response, and metabolic status. These findings revealed the heterogeneity of tissue-resident microbiota and their critical role in CRC progression, highlighting potential avenues for targeted intervention.
- 7 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessTissue-resident microbiota impacts colorectal cancer progression and prognosis
To deepen the understanding of tissue-resident microbiota in colorectal cancer (CRC), we analyzed whole-genome and transcriptome data from 937 patients. We identified 249 genera and 361 species commonly present in both tumors and adjacent normal tissues (NATs). Distinct microbial signatures were associated with anatomical location, tumor stages, hypermutation status, mutations in CRC driver and DNA damage repair genes, as well as consensus molecular subtypes (CMSs). Notably, the presence of the pks island and elevated abundance of Enterobacteriaceae were linked to poor prognosis specifically in CMS2 tumors. Finally, microbial risk scores derived from taxa present in tumor or NATs predicted patient prognosis independently of established clinico-molecular factors. Prognostic taxa were strongly associated with tumor transcriptomic pathways related to hypoxia, immune response, and metabolic status. These findings revealed the heterogeneity of tissue-resident microbiota and their critical role in CRC progression, highlighting potential avenues for targeted intervention.
- Open Access
Deciphering unique and shared interactions between the human gut microbiota and oral antidiabetic drugs
The administration of oral antidiabetic drugs (OADs) to patients with type 2 diabetes elicits distinct and shared changes in the gut microbiota, with acarbose and berberine exhibiting greater impacts on the gut microbiota than metformin, vildagliptin, and glipizide. The baseline gut microbiota strongly associates with treatment responses of OADs.
Open AccessDeciphering unique and shared interactions between the human gut microbiota and oral antidiabetic drugs
The administration of oral antidiabetic drugs (OADs) to patients with type 2 diabetes elicits distinct and shared changes in the gut microbiota, with acarbose and berberine exhibiting greater impacts on the gut microbiota than metformin, vildagliptin, and glipizide. The baseline gut microbiota strongly associates with treatment responses of OADs.